Indication
Ciprofast® is indicated in the treatment of a wide range of infections including:
- Biliary tract infection.
- Gastro enteritis (including diarrhoea, campylobacter enteritis, salmonella enteritis and shigellosis)
- Meningitis, otitis media, peritonitis and Q fever.
- Lower respiratory tract infections.
- Skin infections (including soft-tissue infections.)
- Typhoid and paratyphoid fever.
- Genito-urinary tract infections including gonorrhea.
- Eye infections.
- Oral and dental infections.
- Bone and joint infections.
Composition
Each film coated tablet Ciprofast® 250 contains:
- Ciprofloxacin 250 mg (as Ciprofloxacin HCl )
Each film coated tablet Ciprofast® 500 contains:
- Ciprofloxacin 500 mg (as Ciprofloxacin HCl )
Each film coated tablet Ciprofast® 750 contains:
- Ciprofloxacin 750 mg (as Ciprofloxacin HCl )
Dosage
¤ Ciprofast® should be taken with meals. Patients should maintain an adequate fluid intake during treatment, and avoid the concomitant use of aluminum and magnesium hydroxides.
- The usual adult oral dose of Ciprofast® ranges from 250 to 750 mg twice daily depending on the severity and nature of the infection.
- Single oral doses of 250 or 500 mg are used for the treatment of gonorrhoeae.
- A single oral dose of 500 mg is suggested for meningococcal meningitis prophylaxis.
- Doses should be reduced in patients with severe renal impairment. Halving the dose has been suggested when the creatinine clearance is less than 20 ml/minute or alternatively the dosage interval may be increased.
¤ Generally Ciprofast® should be continued for at least 2-days after the signs and symptoms of infection have disappeared.
- Ciprofloxacin is a fluorinated-4-quinolone or fluoroquinolone antibacterial with a wider spectrum of activity than nalidixic acid and more favourable pharmacokinetics for use in systemic infection.
- Ciprofloxacin is rapidly and well absorbed from the gastrointestinal tract. Oral bioavailability is approximately 70% and a peak plasma concentration of about 2.5 μg/ml is achieved 1 to 2 hours after a dose of 500 mg by mouth. Absorption may be delayed by the presence of food but not substantially affected overall,
- the plasma half life is about 3.5 to 4.5 hours, but may be prolonged in severe renal failure.
- Plasma protein binding ranges from 20 to 40%.
- Ciprofloxacin is widely distributed in the body, it crosses the placenta and is distributed into breast milk, and high concentrations are achieved in bile.
- Approximately 40 to 50% of an orally administered dose is excreted in urine as unchanged drug.
Each film coated tablet Ciprofast® 250 contains:
- Ciprofloxacin 250 mg (as Ciprofloxacin HCl )
Each film coated tablet Ciprofast® 500 contains:
- Ciprofloxacin 500 mg (as Ciprofloxacin HCl )
Each film coated tablet Ciprofast® 750 contains:
- Ciprofloxacin 750 mg (as Ciprofloxacin HCl )
Ciprofast® is indicated in the treatment of a wide range of infections including:
- Biliary tract infection.
- Gastro enteritis (including diarrhoea, campylobacter enteritis, salmonella enteritis and shigellosis)
- Meningitis, otitis media, peritonitis and Q fever.
- Lower respiratory tract infections.
- Skin infections (including soft-tissue infections.)
- Typhoid and paratyphoid fever.
- Genito-urinary tract infections including gonorrhea.
- Eye infections.
- Oral and dental infections.
- Bone and joint infections.
Ciprofast® is contraindicated in
- patients with a history of hypersensitivity to Ciprofloxacin or other quinolone derivatives.
- Epileptics and patients with pre-existing CNS lesions.
- Children, adolescent, pregnant or breast-feeding mothers.
- Fluroquinolones are known to inhibit hepatic drug metabolism and may interfere with the clearance of drugs metabolized by the liver such as theophylline.
- On the other hand, Cations like aluminum, magnesium, or iron reduce the absorption of Ciprofast® and related drugs when given concomitantly.
- Ciprofast® should be used during pregnancy only if clearly needed.
- Ciprofast® is excreted in breast milk and should be used with caution in lactating mothers.
As with other quinolones, side effects are usually:
- Gastrointestinal disturbances include: nausea, vomiting, diarrhoea, abdominal pain and dyspepsia.
- Headache, dizziness and restlessness are among the commonest effects on the CNS.
- Hypersensitivity type reactions affecting the skin, in addition to rash and pruritus.
¤ Ciprofast® should be taken with meals. Patients should maintain an adequate fluid intake during treatment, and avoid the concomitant use of aluminum and magnesium hydroxides.
- The usual adult oral dose of Ciprofast® ranges from 250 to 750 mg twice daily depending on the severity and nature of the infection.
- Single oral doses of 250 or 500 mg are used for the treatment of gonorrhoeae.
- A single oral dose of 500 mg is suggested for meningococcal meningitis prophylaxis.
- Doses should be reduced in patients with severe renal impairment. Halving the dose has been suggested when the creatinine clearance is less than 20 ml/minute or alternatively the dosage interval may be increased.
¤ Generally Ciprofast® should be continued for at least 2-days after the signs and symptoms of infection have disappeared.
¤ Ciprofast® should be used with caution in patients with
- epilepsy
- a history of CNS disorders
- and to those with impaired renal or hepaticfunctions
- glucose-6-phosphate dehydrogenase deficiency
- diabetes.
¤ During treatment, patients should not expose themselves to sunlight, UV rays or sunray lamp (due to photosensitivity reactions.)
¤ Avoid driving or other activities requiring alertness.
¤ Antacid or iron should not be taken within 2 hours of Ciprofast®.
- Ciprofast® Film coated tablet 250 mg ( Blister of 10 Tablets, pack of one blister ).
- Ciprofast® Film coated tablet 500 mg ( Blister of 10 Tablets, pack of one blister ).
- Ciprofast® Film coated tablet 750 mg ( Blister of 10 Tablets, pack of one blister ).
- Store in a dry place at a temperature not exceeding 30° C.